摘要
Abstract
Objective To investigate the factors related to HBV YMDD mutations in chronic hepatitis B patients during lamivudine therapy. Methods One hundred and sixty-nine chronic hepatitis B patients receiving lamivudine therapy for more than one year were retrospectively enrol ed in the study. HBV genotypes, HBV DNA load, HBeAg status, and ALT levels were monitored prior to lamivudine treatment and at every three months during one year of lamivudine therapy. Results Of 169 pa-tients, 76 (44.97%) were infected with genotype B and 93 patients (55.03%) with genotype C. Total 46 patients (27.22%) with YMDD mutants were detected after one year of lamivudine therapy;there were significant differences in the rate of YMDD muta-tions between patients with genotypes B and C (35.53%vs 20.43%, P<0.05). The HBV DNA levels before treatment in patients with YMDD mutants were significantly higher than those in patients without YMDD mutants (7.26 ±0.58 vs 6.44 ±0.65 log copies/ml, P<0.05). Significant difference in the rate of YMDD mutations was observed between the patients with positive HBeAg and patients with negative HBeAg (38.10%vs 20.75%, P<0.05). No significant difference in the ALT levels were observed be-tween the patients with YMDD mutants and without YMDD mutants (136.09±28.21 vs 124.15±26.52 U/L, P>0.05). Conclusion HBV genotypes, HBV DNA levels, and HBeAg status are strongly correlated with the emergence of YMDD mutations in chronic hepatitis B patients during lamivudine therapy.关键词
慢性乙型肝炎/拉米夫定/YMDD变异/相关因素/基因型Key words
Chronic hepatitis B/Lamivudine/YMDD mutations/Relative factors/Genotypes
